Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, et al. EAU - ESTRO - ESUR - SIOG guidelines on prostate cancer 2018. In: European Association of Urology guidelines 2018 Edition Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2018.
Brizmohun Appayya M, Adshead J, Ahmed HU, Allen C, Bainbridge A, Barrett T, et al. National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. BJU Int 2018; 122: 13-25. 10.1111/bju.14361
Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 2007; 25: 110-4. 10.1016/j.urolonc.2006.06.003
Godoy G, Tareen BU, Lepor H. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. BJU Int 2009; 104: 1610-4. 10.1111/j.1464-410X.2009.08688.x
Epstein JI, Partin AW, Potter SR, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology 2000; 56: 283-8. 10.1016/S0090-4295(00)00640-3
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-75. 10.1016/j.juro.2010.10.057
Morlacco A, Sharma V, Viers BR, Rangel LJ, Carlson RE, Froemming AT, et al. The incremental role of magnetic resonance imaging for prostate cancer staging before radical prostatectomy. Eur Urol 2017; 71: 701-4. 10.1016/j.eururo.2016.08.015
Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-6. 10.1111/j.1464-410X.2005.05394.x
Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the partin tables. Acta Radiol 2009; 50: 562-9. 10.1080/02841850902889846
Rayn KN, Bloom JB, Gold SA, Hale GR, Baiocco JA, Mehralivand S, et al. Added value of multiparametric magnetic resonance imaging to clinical nomograms for predicting adverse pathology in prostate cancer. J Urol 2018; 200: 1041-7. 10.1016/j.juro.2018.05.094
Mottet N, van der Poel HG, Rouvière O, Matveev VB, Schoots IG, Briers E, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 2017; 72: 84-109. 10.1016/j.eururo.2016.12.003
Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 245-53. 10.3322/caac.21391
Giganti F, Moore CM, Punwani S, Allen C, Emberton M, Kirkham A. The natural history of prostate cancer on MRI: lessons from an active surveillance cohort. Prostate Cancer Prostatic Dis 2018; 21: 556-63. 10.1038/s41391-018-0058-5
Turkbey B, Merino MJ, Gallardo EC, Shah V, Aras O, Bernardo M, et al. Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging 2014; 39: 1443-8. 10.1002/jmri.24317
Czarniecki M, Caglic I, Grist JT, Gill AB, Lorenc K, Slough RA, et al. Role of PROPELLER-DWI of the prostate in reducing distortion and artefact from total hip replacement metalwork. Eur J Radiol 2018; 102: 213-9. doi:org/10.1016/j.ejrad.2018.03.021
Gill AB, Czarniecki M, Gallagher FA, Barrett T. A method for mapping and quantifying whole organ diffusion-weighted image distortion in MR imaging of the prostate. Sci Rep 2017; 7: 12727. 10.1038/s41598-017-13097-6
Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 0232: 1-12. 10.1016/j.eururo.2019.02.033
Caglic I, Povalej Brzan P, Warren AY, Bratt O, Shah N, Barrett T. Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension. Eur Radiol 2019. [Epub ahead of print]. 10.1007/s00330-019-06070-6
Dyde R, Chapman AH, Gale R, Mackintosh A, Tolan DJM. Precautions to be taken by radiologists and radiographers when prescribing hyoscine-N-butyl-bromide. Clin Radiol 2008; 63: 739-43. org/10.1016/j.crad.2008.02.008
Rosenkrantz AB, Shanbhogue AK, Wang A, Kong MX, Babb JS, Taneja SS. Length of capsular contact for diagnosing extraprostatic extension on prostate MRI: assessment at an optimal threshold. J Magn Reson Imaging 2016; 43: 990-7. 10.1002/jmri.25040
Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 2013; 111: 22-9. 10.1111/j.1464-410X.2012.11324.x
Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR, et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013; 268: 144-52. 10.1148/radiol.13121325
de Rooij M, Hamoen EHJ, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 2016; 70: 233-45. 10.1016/j.eururo.2015.07.029
Lawrence EM, Gallagher FA, Barrett T, Warren AY, Priest AN, Goldman DA, et al. Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate - or high-risk prostate cancer. AJR Am J Roentgenol 2014; 203: W280-6. 10.2214/AJR.13.11754
Boesen L, Chabanova E, Løgager V, Balslev I, Mikines K, Thomsen HS. Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology. Eur Radiol 2015; 25: 1776-85. 10.1007/s00330-014-3543-9
Schieda N, Quon JS, Lim C, El-Khodary M, Shabana W, Singh V, et al. Evaluation of the European Society of Urogenital Radiology (ESUR) PI-RADS scoring system for assessment of extra-prostatic extension in prostatic carcinoma. Eur J Radiol 2015; 84: 1843-8. 10.1016/j.ejrad.2015.06.016
Baco E, Rud E, Vlatkovic L, Svindland A, Eggesbø HB, Hung AJ, et al. Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer. J Urol 2015; 193: 46672. 10.1016/j.juro.2014.08.084
Woo S, Kim SY, Cho JY, Kim SH. Length of capsular contact on prostate MRI as a predictor of extracapsular extension: which is the most optimal sequence? Acta Radiol 2017; 58: 489-97. 10.1177/0284185116658684
Matsuoka Y, Ishioka J, Tanaka H, Kimura T, Yoshida S, Saito K, et al. Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI diagnosis for extracapsular extension of prostate cancer. AJR Am J Roentgenol 2017; 209: W76-84. org/10.2214/AJR.16.17163
Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergenvan de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-61. 10.1148/radiol.11091409
Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 2011; 196: 374-81. 10.2214/AJR.10.4441
Kim CK, Park SY, Park JJ, Park BK. Diffusion-weighted MRI as a predictor of extracapsular extension in prostate cancer. AJR Am J Roentgenol 2014; 202: W270-6. 10.2214/AJR.13.11333
Woo S, Cho JY, Kim SY, Kim SH. Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging. AJR Am J Roentgenol 2015; 204: W168-75. 10.2214/AJR.14.12939
Giganti F, Coppola A, Ambrosi A, Ravelli S, Esposito A, Freschi M, et al. Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: development and external validation of a nomogram of clinical use. Urol Oncol Semin Orig Investig 2016; 34: 291. e9-17. 10.1016/j.urolonc.2016.02.015
Barrett T, Priest AN, Lawrence EM, Goldman DA, Warren AY, Gnanapragasam VJ, et al. Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. AJR Am J Roentgenol 2015; 205: W585-93. 10.2214/AJR.15.14338
Rosenkrantz AB, Neil J, Kong X, Melamed J, Babb JS, Taneja SS, et al. Prostate cancer: comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. AJR Am J Roentgenol 2010; 194: 446-52. 10.2214/AJR.09.3217
Liberatore M, Delongchamps NB, Eiss D, Beuvon F, Zerbib M, Flam T, et al. Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D’Amico tumor risk criteria? Eur J Radiol 2011; 81: e591-7. 10.1016/j.ejrad.2011.06.056
Jäderling F, Nyberg T, Öberg M, Carlsson S, Skorpil M, Blomqvist L. Accuracy in local staging of prostate cancer by adding a three-dimensional T2-weighted sequence with radial reconstructions in magnetic resonance imaging. Acta Radiol Open 2018; 7: 205846011875460. 10.1177/2058460118754607
Peng Y, Schmid-Tannwald C, Wang S, Antic T, Jiang Y, Eggener S, et al. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology 2013; 267: 797-806. 10.1148/radiol.13121319
Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisenberg HF, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007; 242: 182-8. 10.1148/radiol.2421051254
Grivas N, Hinnen K, de Jong J, Heemsbergen W, Moonen L, Witteveen T, et al. Seminal vesicle invasion on multi-parametric magnetic resonance imaging: correlation with histopathology. Eur J Radiol 2018; 98: 107-12. 10.1016/j.ejrad.2017.11.013
Roethke M, Kaufmann S, Kniess M, Ketelsen D, Claussen CD, Schlemmer HP, et al. Seminal vesicle invasion: accuracy and analysis of infiltration patterns with high-spatial resolution T2-weighted sequences on endorectal magnetic resonance imaging. Urol Int 2014; 92: 294-9. 10.1159/000353968
Ohori M, Scardino PT, Lapin SL, Seale-Hawkins C, Link J, Wheeler TM. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 1993; 17: 1252-61. 10.1097/00000478-199312000-00006
Jung DC, Lee HJ, Kim SH, Choe GY, Lee SE. Preoperative MR imaging in the evaluation of seminal vesicle invasion in prostate cancer: pattern analysis of seminal vesicle lesions. J Magn Reson Imaging 2008; 28: 144-50. 10.1002/jmri.21422
Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I, et al. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology 2013; 267: 797-806. 10.1148/radiol.13121319
Medved M, Sammet S, Yousuf A, Oto A. MR Imaging of the prostate and adjacent anatomic structures before, during, and after ejaculation: qualitative and quantitative evaluation. Radiology 2014; 271: 452-60. 10.1148/radiol.14131374
Shin T, Kaji Y, Shukuya T, Nozaki M, Soh S, Okada H. Significant changes of T2 value in the peripheral zone and seminal vesicles after ejaculation. Eur Radiol 2018; 28: 1009-15. 10.1007/s00330-017-5077-4
Kabakus IM, Borofsky S, Mertan FV, Greer M, Daar D, Wood BJ, et al. Does abstinence from ejaculation before prostate MRI improve evaluation of the seminal vesicles? AJR Am J Roentgenol 2016; 207: 1205-9. 10.2214/AJR.16.16278
Joniau S, Van den Bergh L, Lerut E, Deroose CM, Haustermans K, Oyen R, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013; 63: 450-8. 10.1016/j.eururo.2012.06.057
Briganti A, Suardi N, Capogrosso P, Passoni N, Freschi M, Di Trapani E, et al. Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum. Prostate 2012; 72: 186-92. 10.1002/pros.21420
Barentsz JO, Severens JL, Hoogeveen YL, Hövels AM, Adang EM, Jager GJ, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387-95. 10.1016/j.crad.2007.05.022
Vag T, Heck MM, Beer AJ, Souvatzoglou M, Weirich G, Holzapfel K, et al. Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol 2014; 24: 1821-6. 10.1007/s00330-014-3240-8
Eiber M, Beer AJ, Holzapfel K, Tauber R, Ganter C, Weirich G, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 2010; 45: 15-23. 10.1097/RLI.0b013e3181bbdc2f
Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in 11C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 2011; 13: 352-61. 10.1007/s11307-010-0337-6
Vallini V, Ortori S, Boraschi P, Manassero F, Gabelloni M, Faggioni L, et al. Staging of pelvic lymph nodes in patients with prostate cancer: usefulness of multiple b value SE-EPI diffusion-weighted imaging on a 3.0 T MR system. Eur J Radiol Open 2016; 3: 16-21. 10.1016/j.ejro.2015.11.004
Roy C, Bierry G, Matau A, Bazille G, Pasquali R. Value of diffusion-weighted imaging to detect small malignant pelvic lymph nodes at 3 T. Eur Radiol 2010; 20: 1803-11. 10.1007/s00330-010-1736-4
Kwee TC, Takahara T, Luijten PR, Nievelstein RAJ. ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol 2010; 75: 215-20. 10.1016/j.ejrad.2009.03.026
Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B. Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging 2011; 33: 128-35. 10.1002/jmri.22395
Sadinski M, Medved M, Karademir I, Wang S, Peng Y, Jiang Y, et al. Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging 2015; 40: 2523-8. 10.1007/s00261-015-0396-x
von Below C, Daouacher G, Wassberg C, Grzegorek R, Gestblom C, Sörensen J, et al. Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer. Clin Radiol 2016; 71: 328-34. 10.1016/j.crad.2015.12.001
Sushentsev N, Martin H, Rimmer Y, Barrett T. Added value of diffusion-weighted MRI for nodal radiotherapy planning in pelvic malignancies. Clin Transl Oncol 2019. [Epub ahead of print]. doi.org/10.1007/s12094-019-02068-0
Zacharias C, Kunder C, Giesel F, Daniel B, Hatami N, Harrison C, et al. Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology 2018; 288: 495-505. org/10.1148/radiol.2018172232
Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 70-83. 10.1007/s00259-015-3206-3
Baltzer P, Kenner L, Hartenbach M, Mitterhauser M, Goldner GM, Grahovac M, et al. PSMA Ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res 2018; 24: 6300-7. 10.1158/1078-0432.ccr-18-0768
Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-9. 10.1056/NEJMoa022749
Birkhäuser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013; 64: 953-60. 10.1016/j.eururo.2013.07.032
Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009; 55: 761-9. 10.1016/j.eururo.2008.12.034
Fortuin AS, Brüggemann R, van der Linden J, Panfilov I, Israël B, Scheenen TWJ, et al. Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology 2018; 10: e1471. 10.1002/wnan.1471
Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 2014; 43: 1503-13. 10.1007/s00256-014-1903-9
Padhani AR, Koh D-M, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011; 261: 700-18. 10.1148/radiol.11110474
Padhani AR, Lecouvet FE, Tunariu N, Koh D-M, De Keyzer F, Collins DJ, et al. METastasis Reporting and Data System for Prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 2017; 71: 81-92. 10.1016/j.eururo.2016.05.033
Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012; 62: 68-75. 10.1016/j.eururo.2012.02.020
Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 2015; 275: 155-66. 10.1148/radiol.14141242
Larbi A, Pasoglou V, Triqueneaux P, Cyteval C, Tombal B, Omoumi P, et al. Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences. Eur Radiol 2018. [Epub ahead of print]. 10.1007/s00330-018-5796-1